Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
It is among the first new semaglutide treatment options approved in Brazil, in a market worth an estimated USD 1.8 billion1, and paves the way for an expected launch in the second half of 2026
What the evidence actually suggests The strongest clinical evidence supports the idea that GLP-1 medications can improve inflammatory markers in many patients, particularly those with obesity, type 2 diabetes, fatty liver disease, and cardiovascular risk
Other types of liver conditions such as autoimmune hepatitis, HBV/HCV infection, and Wilsons disease differ from NASH and should be excluded from NASH clinical trials
However, researchers note that consistency is a major hurdle, with more than half of users discontinuing the medication within two years, often restarting later
US$ 26.07
US$ 23.25
US$ 25.69
US$ 22.93
US$ 26.22
US$ 20.39
US$ 22.71
US$ 26.41
US$ 22.13
US$ 21.17
